IBRX News and Press, ImmunityBio Inc.

2026-03-05 10:20:00 ET Oncology is the largest therapeutic area in the biopharma industry, in terms of sales. The rapid rise in recent years of drugs to treat diabetes and manage weight loss might disrupt the traditional hierarchy, but it's safe to say that oncology will remain one of the m...

2026-03-03 23:52:12 ET ImmunityBio, Inc. (IBRX) Q4 2025 Earnings Call March 3, 2026 4:30 PM EST Company Participants Patrick Soon-Shiong - Founder, Executive Chairman and Global Chief Scientific & Medical Officer Richard Adcock - President, CEO & Director ......

2026-03-02 17:38:28 ET More on ImmunityBio ImmunityBio: Disconnect Between Clinical Progress And Stock Performance ImmunityBio: The Story Surrounding Anktiva So Far ImmunityBio: Making Strides, But Beware The Hype (Rating Downgrade) Top 10 Healthcare Stocks o...

2026-03-02 15:31:35 ET More on healthcare stocks Sector Rotation: Healthcare XLV Should Be The Next Stop ImmunityBio: Disconnect Between Clinical Progress And Stock Performance VT: Still The Best Approach To Passive Investing Notable healthcare headlines for ...

ImmunityBio, Inc. ( NASDAQ: IBRX ), today announced that it will host a live conference call at 1:30 p.m. Pacific Time on Tuesday, March 3, 2026, to provide a business update, including progress across the company’s clinical trial pipeline, and to review financial results for the year ...

Study fully enrolled ahead of schedule, with 366 of 366 BCG-naïve NMIBC patients randomized to receive BCG alone or ANKTIVA plus BCG Interim analysis requested by the FDA demonstrated a statistically significant improvement in duration of complete response with ANKTIVA plus BCG, with no ...

Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026 Canada NewsWire Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , Feb. 25, 2026 /CNW/ -- Equity Insider News Commentary , The immuno-oncology market is forecast to grow from $65.22 bil...

2026-02-25 07:19:07 ET Overview Stock of ImmunityBio ( IBRX ), despite my past reservations, has tripled since my last look in July 2025.... Read the full article on Seeking Alpha For further details see: ImmunityBio: Disconnect Between Clinical Progress And ...

2026-02-24 19:08:40 ET Denver, Colorado – Markets are experiencing a cross-sector mix of breakthrough science, regulatory acceleration, global expansion, and next-generation infrastructure demand. From advanced materials to immunotherapy and AI-enabling semiconductors, several names ...

2026-02-23 18:33:18 ET Denver, Colorado - Midday trading is being shaped by a powerful mix of biotech momentum, breakthrough materials science, and strategic buyouts, as investors rotate toward companies delivering tangible catalysts. Spider Silk Headlines Power Materials Story ...